Array Biopharma grows revenue 91 percent year over year
BOULDER — Array Biopharma (Nasdaq: ARRY) posted a first-quarter 12 cent loss per share, which still managed to beat analyst expectations by 9 cents.
The company’s net loss was nearly $25 million, an improvement over the same period last year when Array lost nearly $38 million or 22 cents per share. The company also has more shares this year than it did last year.
Although the Boulder biotech company didn’t post strong earnings, the company’s revenue grew 91 percent year over year to $56.9 million, beating analyst expectations by $22.4 million.
SPONSORED CONTENT
People Powered: Preparing Longmont Businesses for Economic Success
Longmont Chamber and FNBO present People Powered on April 24, 2024, aiming to inform business owners about workforce development, housing, and transportation issues.
In September, Array got European Commission approval for the combined use of its drugs, Braftovi and Mektovi. In July, the company launched that combination in the U.S. for certain melanoma patients. Net product sales in the first quarter were $14 million. Array also has a clinical trial going on and expects to analyze the results of that in the first half of 2019.
BOULDER — Array Biopharma (Nasdaq: ARRY) posted a first-quarter 12 cent loss per share, which still managed to beat analyst expectations by 9 cents.
The company’s net loss was nearly $25 million, an improvement over the same period last year when Array lost nearly $38 million or 22 cents per share. The company also has more shares this year than it did last year.
Although the Boulder biotech company didn’t post strong earnings, the company’s revenue grew 91 percent year over year to $56.9 million, beating analyst expectations by $22.4 million.
In September,…
THIS ARTICLE IS FOR SUBSCRIBERS ONLY
Continue reading for less than $3 per week!
Get a month of award-winning local business news, trends and insights
Access award-winning content today!
